PATENT CLAIM ANALYSIS

Application Number: 15885231
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["514", "464000"]

Abstract:
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Claim (Index 8):
The tablet composition of  claim 7 , wherein the naturally occurring material is selected from the group consisting of alginic acid, pectin, xanthan gum, carrageenan, locust bean gum, gum arabic, gum karaya, guar gum, and gum tragacanth.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.80357
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14914416', '15524224', '15728695', '15304613', '14974576']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8014637044175593
- 35 USC 102 Novelty (BERT): 0.5853510645649256
- Combined Prediction Score: 0.779852440432296
- Mean Citation Score: 323.11179
- Max Citation Score: 517.1948
- Similarity Product: 419.37068379268646

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test